ASCO GU 2026: Comparing Safety Profiles of ARPIs in Metastatic Hormone Sensitive Prostate Cancer

Neil Shore from CPI - Carolina Urologic Research Center in South Carolina, presents a matched-adjustment indirect comparison analysis of androgen receptor pathway inhibitors combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. The study shows that darolutamide plus ADT is associated with lower rates of fatigue and rash and a generally favorable safety profile compared with other ARPIs, supporting more informed and individualized treatment selection.